24.65
+0.59(+2.45%)
Currency In USD
| Previous Close | 24.06 |
| Open | 24.24 |
| Day High | 24.74 |
| Day Low | 23.81 |
| 52-Week High | 35.84 |
| 52-Week Low | 14.59 |
| Volume | 275,327 |
| Average Volume | 522,520 |
| Market Cap | 715.05M |
| PE | -72.5 |
| EPS | -0.34 |
| Moving Average 50 Days | 19.59 |
| Moving Average 200 Days | 22.18 |
| Change | 0.59 |
If you invested $1000 in Castle Biosciences, Inc. (CSTL) since IPO date, it would be worth $1,151.87 as of September 10, 2025 at a share price of $24.65. Whereas If you bought $1000 worth of Castle Biosciences, Inc. (CSTL) shares 5 years ago, it would be worth $503.16 as of September 10, 2025 at a share price of $24.65.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions
GlobeNewswire Inc.
Yesterday at 11:00 AM GMT
In the study, TissueCypher identified that 15% of patients with non-dysplastic Barrett's esophagus (NDBE) had a probability of progression that was similar to, or exceeded, progression rates associated with low-grade dysplasia (LGD); current guidelin
New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma
GlobeNewswire Inc.
Aug 25, 2025 11:00 AM GMT
New validation study shows DecisionDx-SCC significantly outperforms current staging systems in predicting risk of local recurrence and metastasis for NCCN high-risk patients Clinician survey confirms test results align with treatment decision-making
Castle Biosciences to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Aug 21, 2025 11:00 AM GMT
FRIENDSWOOD, Texas, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a comp